Published on Friday February 05, 2016

Smooth initiates a phase III trial in non-alcoholic fatty liver disease

Smooth Drug Development initiates a phase III trial in patients with Non-alcoholic fatty liver disease and metabolic syndrome.

It is planned to enroll 160 patients at 15 sites across Russia. Smooth Drug Development is providing a full spectrum of clinical trial services for this trial.
Phase III are planned for obtaining of Marketing Authorization after the drug has proven safety and efficacy in phase II and optimal doses and administration mode are determined.
Smooth Drug Development is a leading regional CRO, conducts clinical trials since 2011.